CD134 agonists alone have modest anti-tumour effects7,8, and are routinely used in combination with other agents to show efficacy e.g. with CpG and anti-CTLA-49, with anti-HER2 and CTLA-410, or with GITR stimulation11. Here, TNFRSF4 is linked to neoplasm.